

Clinical Trials in Psychopharmacology

A Better Brain

SECOND EDITION

Editors

Marc Hertzman

*Research Psychiatrist and formerly Professor of Psychiatry,
George Washington University, USA*

Lawrence Adler

University of Maryland School of Medicine, USA



WILEY-
BLACKWELL

Clinical Trials in Psychopharmacology

SECOND EDITION

Clinical Trials in Psychopharmacology

A Better Brain

SECOND EDITION

Editors

Marc Hertzman

*Research Psychiatrist and formerly Professor of Psychiatry,
George Washington University, USA*

Lawrence Adler

University of Maryland School of Medicine, USA



WILEY-
BLACKWELL

This edition first published 2010
© 2010 John Wiley & Sons, Ltd

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical and Medical business with Blackwell Publishing.

Registered office:

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Other Editorial Offices:

9600 Garsington Road, Oxford, OX4 2DQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell.

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloguing-in-Publication Data

Clinical trials in psychopharmacology : a better brain / editors, Marc Hertzman, Lawrence Adler. – 2nd ed.
p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-470-74076-7 (cloth)

1. Psychopharmacology. 2. Psychotropic drugs. 3. Clinical trials. I. Hertzman, Marc. II. Adler, Lawrence.

[DNLM: 1. Psychotropic Drugs. 2. Clinical Trials as Topic. QV 77.2 C6416 2010]

RM315.C557 2010

615'.78 – dc22

2009031413

ISBN: 978-0-470-74076-7

A catalogue record for this book is available from the British Library.

Typeset in 10.5/12.5pt Times by Laserwords Private Limited, Chennai, India.

Printed in Singapore by Markono Print Media Pte Ltd

First impression – 2010

Contents

Acknowledgments	xi
Introduction	xiii
List of Contributors	xv
SECTION I: The Health Care Environment and Medications	1
1. FDA Reform: Déjà vu Encore	3
<i>John J. Cahrssen</i>	
1.1 Introduction	4
1.2 The 1992 prescription drug user fee act adds funds and changes FDA's focus	7
1.3 PDUFA shortens drug review times and eliminates the drug lag	8
1.4 PDUFA timetables feed safety concerns	9
1.5 FDA responds to safety concerns	11
1.6 The pipeline problem	12
1.7 The 2007 FDA Science Board's Subcommittee on Science and Technology report	17
1.8 The FDAAA of 2007 reauthorize PDUFA and provide new authority to address safety and the critical path initiative	18
1.9 The impact of PDFUA on FDA	21
1.10 Comparative medical benefits, comparative effectiveness and FDA	21
1.11 FDA and non-inferiority trials	23
1.12 FDA and CMS decisions on Medicare coverage	24
1.13 Preemption: FDA's role in relation to liability litigation in state courts	24
1.14 FDA's exclusivity in allowing access to experimental drugs	24
1.15 Conclusions	25
2. Do Antidepressants Cause Suicide?	31
<i>Marc Hertzman</i>	
2.1 Some definitional problems	31

2.2	A brief history of the concerns of suicidality caused by antidepressants	32
2.3	Politics rears its ugly head	35
2.4	The FDA responds	35
2.5	What changes in public policy wrought	36
2.6	A funny thing happened on the way to the forum	39
2.7	Meanwhile back at the ranch	39
2.8	Moral (maybe)	40
3.	The Genome, Genes and Brain – Tailored Drugs	43
	<i>Lawrence Adler</i>	
3.1	Introduction	43
3.2	Issues in new drug development	44
3.3	Early development of psychiatric pharmaceutical entities	44
3.4	Advances in research technology	45
3.5	Review of genetics	46
3.6	Activation of genes by signal transduction cascades	47
3.7	The human genome	48
3.8	The sequencing of the genome	48
3.9	DNA variation	48
3.10	Genes and illness	49
3.11	Genomic findings, potential targets and new drug development	50
3.12	Conclusion	55
4.	Patenting and Licensing Concerns in Psychiatric Genetics	61
	<i>Jorge A. Goldstein and Karen R. Markowicz</i>	
4.1	Genetic diagnoses in psychiatry	62
4.2	The evolving patent landscape in psychiatry	63
4.3	Approaches to solving potential problems	76
4.4	Conclusions	83
5.	Women’s Issues in Clinical Trials	87
	<i>Mary V. Seeman</i>	
5.1	History	87
5.2	Perceived advantages of excluding women	90
5.3	Change in perspective	90
5.4	Have things changed?	91
5.5	Progress since 1993	92
5.6	Reported current difficulties in including women	93
5.7	Contraception in clinical trials	94
5.8	Drugs in lactating women	95
5.9	How often do women take drugs during pregnancy?	96
5.10	Ethical issues: risk/benefit analysis	96

5.11	Adequate information	97
5.12	Adolescent women	97
5.13	Recruitment and retention of women	97
SECTION II: Clinical Trials and Mood Disorders		103
6.	Issues and Clues in the Pharmacological Treatment of Mood Disorders	105
	<i>Fabrice Jollant, Adéla Ionita and Philippe Courtet</i>	
6.1	What do we know about mood disorders that may be relevant for their pharmacological treatment?	106
6.2	Are there clues for the pharmacological treatment of mood disorders?	109
6.3	Perspectives	116
7.	Bipolar Disorder	125
	<i>Alberto Bocchetta</i>	
7.1	Introduction	126
7.2	Trials in acute mania	127
7.3	Trials in acute bipolar depression	130
7.4	Trials in maintenance of bipolar disorder	132
7.5	What is a mood stabilizer?	134
7.6	What controlled trials cannot tell us about treatment of bipolar disorder	135
8.	Special Issues of Research Methodology in Bipolar Disorder Clinical Treatment Trials	149
	<i>Robert M. Post</i>	
8.1	Introduction	150
8.2	Efficacy–effectiveness gap	151
8.3	Trials for drug registration versus those that are most clinically informative	151
8.4	The need for designs that more optimally inform clinical practice	152
8.5	‘Hidden’ high degrees of treatment resistance	153
8.6	Controversy about optimal designs and rating instruments	154
8.7	The traditional RCT is expensive, cumbersome and prone to failure	156
8.8	Alternative designs for pilot and proof of principle efficacy studies	156
8.9	Statistical analysis of N-of-1 trials	159
8.10	Statistical approaches to estimating necessary trial durations in individual patients	160
8.11	Crossover trials for enhancing clinical informatics and statistical power	161
8.12	Carryover effects	164
8.13	Long-term trend in studies of bipolar disorder compared to other major mental disorders	165

8.14	Parallel and pressing design issues for childhood-onset bipolar illness	166
8.15	Contradictory balance between inclusiveness (for generalizability) and homogeneity (for efficacy)	167
8.16	Assessing moderators and mediators	167
8.17	Conclusions and implications	169
9.	The Utility of Low-dose Antidepressants	179
	<i>Monica L. Zilberman, Clarice Gorenstein and Valentim Gentil</i>	
9.1	Introduction	179
9.2	Low dose antidepressants for chief indications	180
9.3	Antidepressant use for other indications	180
9.4	Emotion regulation in healthy individuals	184
9.5	Conclusion	185
	SECTION III: Clinical Trials in Anxiety and Other Disorders	189
10.	Clinical Trials for Anxiety Disorders	191
	<i>Marco Mula and Gionata Strigaro</i>	
10.1	Introduction	191
10.2	Methodological issues in treatment research for anxiety disorders	192
10.3	Panic disorder with/without agoraphobia	197
10.4	Generalized anxiety disorder	198
10.5	Social anxiety disorder	199
10.6	Post-traumatic stress disorder	200
10.7	Conclusions	201
10.8	Acknowledgment	202
11.	Pharmacological Trials for the Treatment of Substance Use Disorders	207
	<i>Lisa J. Merlo, Julia Arana and Amanda M. Stone</i>	
11.1	Psychopharmacological trials for the treatment of substance use disorders	208
11.2	Definitions of substance use disorders	208
11.3	Introduction to psychopharmacotherapy for SUDs	209
11.4	Considerations in pharmacotherapy trials for SUDs	219
11.5	Conclusions and future directions	227
12.	Clinical Psychopharmacology of Patients with Eating Disorders	233
	<i>James E Mitchell, Kristine Steffen, Scott Engel, Ross Crosby and James Roerig</i>	
12.1	Introduction	233
12.2	Diagnostic issues	234